ArticleBMC cancer2025

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Ameya D Puranik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.